knowledge -WSS

knowledge

author：explore 2025-09-02 17:43:50 - browse：51

Boston Globe

A commonly prescribed medication for children’s asthma is disappearing from pharmacists’ shelves, forcing parents and pediatricians to scramble for alternatives just as allergy season is about to start.

In a move unusual for such a widely used drug, GlaxoSmithKline discontinued Flovent HFA, the brand name of its corticosteroid treatment fluticasone propionate, at the end of December. Critics, including Massachusetts Senator Elizabeth Warren, say the decision helps the company avoid new Medicaid penalties going into effect this year for medications with price increases that outpace inflation.

“It was all very confusing, and we were left scrambling, trying to find out what we could do,” said Simone Fung, whose 5-year-old son, David, endured worse asthma symptoms over the past two months as the Cambridge family navigated confusing insurance policies and shortages of alternative medications to find a replacement for Flovent.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Medical student insurance fails on mental health care coverage

focus

WSS

FDA panel to weigh approval of NurOwn, controversial ALS drug

Hearing on Medicare drug price negotiation gets unusually heated

Biotech lab space demand falls sharply

Biotech lab space demand falls sharply

Ukraine and a new approach to mental health in war

Second xenotransplant done with gene

entertainment

knowledge

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Target recalls 2.2 million additional candles due to laceration, burn hazards

Sports medicine is finally prioritizing gender equality

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Virginia high school admissions case could be legal follow

Pharma budget tightening trickles down to Doximity

Apple is now the first public company to be valued at $3 trillion

CDC overhauls leadership of center that led response to Covid

Medicare details structure of new drug price negotiation program

How Vertex's cystic fibrosis drug is changing patients' lives

Wikipedia

Maui funeral service workers on devastation of fires: 'I'm in shock'

CommonSpirit Health keeps growing, even as it loses money

Novo acquires Inversago for up to $1 billion

Changes to biosimilar regulatory framework must prioritize patients

Target recalls 2.2 million additional candles due to laceration, burn hazards

CDC overhauls leadership of center that led response to Covid

focus

hotspot

focus

hotspot